The Global Initiative for Asthma, an organization that works with healthcare professionals and public health officials around the world to reduce asthma prevalence, morbidity, and mortality, defines asthma as a chronic disease wherein an individual experiences wheezing, shortness of breath, tightness in the chest, and coughing over a period of time. The symptoms worsen due to the increased secretion of mucus, bronchoconstriction, and the thickening of the walls of the airways, resulting in difficulty exhaling. According to the American Academy of Allergy, Asthma, and Immunology, asthma is classified into four types: exercise induced, allergic, occupational, and childhood. The Asthma and Allergy Foundation of America further segments the disease into two categories, allergic and non-allergic. Asthma can be controlled using preventive medications, which should be administered regularly.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

Breakthrough in asthma research

Asthma: An overview

PART 05: Pipeline portfolio

PART 06: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 07: Key buying criteria for asthma drugs

PART 08: Market segmentation by type of treatment

Preventive medications

Quick-relief medications

Others

PART 09: Market segmentation by drug class

Combination therapies

Bronchodilators

Immunosuppressants

Leukotriene antagonists

Mast cell stabilizers

PART 10: Segmentation by route of administration

Inhalation

Parenteral

Oral

PART 11: Drug delivery devices market for asthma drugs

Market overview

Market segmentation by product type

PART 12: Geographical segmentation

Global asthma therapeutics market by geography 2015-

2020

Asthma therapeutics market in Americas

Asthma therapeutics market in EMEA

Asthma therapeutics market in APAC

PART 13: Market drivers

Huge market potential for mAbs

New product approvals minimizing the impact of generic

erosion

Increasing rate of allergies due to environmental

pollution

PART 14: Impact of drivers

PART 15: Market challenges

Increased preference for CAM

Poor patient adherence toward controller medications

Presence of different phenotypes of asthma leading to

prescription errors

PART 16: Impact of drivers and challenges

PART 17: Market trends

Innovative technologies for drug delivery

Growing adoption of immunotherapies

Shift toward immune/inflammatory system targets from

glucocorticoid and adrenergic receptors

Increase in online marketing services

Growing use of home healthcare devices

PART 18: Vendor landscape

Competitive scenario

Key news

PART 19: Key vendor analysis

AstraZeneca

Boehringer Ingelheim

F. Hoffmann-La Roche

GSK

Merck

Other prominent vendors

PART 20: Appendix

List of abbreviations

PART 21: Explore Technavio